search
Back to results

RCT With 3 Different Biomaterials for Maxillary Sinus Lift

Primary Purpose

Alveolar Bone Atrophy

Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Maxillary Sinus Augmentation
Maxillary Sinus Graft with ABBM
Maxillary Sinus Graft with TCP
Maxillary Sinus Graft with TCP + HA
Sponsored by
University of Pisa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Alveolar Bone Atrophy focused on measuring Bone regeneration, Biomaterial(s), Implantology, Osseointegration

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • need for maxillary sinus augmentation
  • 18 years or older
  • residual ridge height less than 3mm

Exclusion Criteria:

  • full contraindication to implant surgery,
  • systemic diseases that could negatively influence wound healing;
  • heavy smokers (more than 10 cigarettes/day);
  • head and neck irradiation treatment;
  • uncontrolled diabetes;
  • chronic or acute sinus pathology;
  • uncontrolled periodontal disease;
  • full mouth plaque and bleeding score higher than 25%,
  • tooth extractions in the previous 2 months

Sites / Locations

  • University of Geneva

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Control group

Test group 1

Test group 2

Arm Description

patients in the control group received Demineralized Bovine Bone Mineral for the maxillary sinus augmentation

patients in the test group 1 received TCP with particle size from 250 to 1000 µm

patients in the test group 2 received TCP as in test group1 plus crosslinked Hyaluronic Acid

Outcomes

Primary Outcome Measures

Histomorphometric parameters of the augmented bone (descriptive)
Descriptive analysis of the specimen section at the microscope
Histomorphometric parameters of the augmented bone (% of new bone, marrow, graft)
Percentages of newly formed bone, marrow spaces and residual graft particles are reported.

Secondary Outcome Measures

Mean bone gain measured at 9 months through CBCT evaluation
radiographic evaluation
Intra-operative
clinical evaluation (yes/no) of the presence or occurrence of: sinus membrane perforation, excessive bleeding, lateral sinus cortical bone fracture.
Post-operative complications
clinical evaluation (yes/no) of the presence or occurrence of:symptoms of acute sinusitis, swelling, suppuration, bleeding, trismus, hematoma, wound dehiscence, acute infections.
Post-operative complications
clinical evaluation (yes/no) of the presence or occurrence of:symptoms of chronic sinusitis, swelling, suppuration, wound dehiscence, acute infections.
Implant insertion torque measured in Ncm
clinical evaluation
Early implant failure
clinical evaluation of the osseointegration of the implant into the bone (yes/no)
Patient reported outcome measures
All patients will answer a questionnaire regarding the oral health-related quality of life using the 14 questions of the short-form Oral Health Impact Profile (OHIP-14) (This questionnaire consists of 14 questions each one formulated in the following way: "How often (impact item) because of problems with your teeth, mouth or dentures?" The impact items belong to 7 different impact domains: 1. Functional limitations; 2. Physical pain; 3. Psychological discomfort; 4. Physical disability; 5. Psychological disability; 6. Social disability; 7. Handicap. Each question can be answered with a score from 0 to 4 corresponding to: 0 = never, 1 = hardly ever, 2 = occasionally, 3 = fairly often, and 4 = very often.)

Full Information

First Posted
July 22, 2020
Last Updated
August 6, 2020
Sponsor
University of Pisa
search

1. Study Identification

Unique Protocol Identification Number
NCT04506827
Brief Title
RCT With 3 Different Biomaterials for Maxillary Sinus Lift
Official Title
Maxillary Sinus Augmentation With Three Different Biomaterials: Histologic, Histomorphometric, Clinical and Patient Reported Outcomes From a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
February 23, 2017 (Actual)
Primary Completion Date
June 29, 2019 (Actual)
Study Completion Date
December 14, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pisa

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background: Lateral maxillary sinus augmentation (MSA) is a predictable bone regeneration technique in case of atrophy of the posterior-upper maxilla. Aimed at obtaining quantity and quality of bone suitable for receiving osseointegrated implants, its success is largely due to the skill of the surgeon, but also to the characteristics of the biomaterial used. Methods: Twenty-four patients needing MSA were included in the study. The patients were randomly allocated to 3 different groups: Anorganic Bovine Bone Mineral (ABBM) as control, Tricalcium Phosphate (TCP) with or without hyaluronic acid (HA) as test groups. Nine months after MSA bone biopsies were harvested for the histomorphometric analysis. Secondary outcomes were mean bone gain, intraoperative and post-operative complications, implant insertion torque, implant failure and patient related outcome measures (PROMs).
Detailed Description
The implant-prosthetic rehabilitation of the atrophic maxilla requires the creation of sufficient volumetric quantity of bone, through regeneration techniques, necessary to position the implants. Maxillary sinus augmentation (MSA) is probably the most predictable and best performing technique. The present randomized controlled study aims to evaluate and compare, histomorphometrically and clinically three different bone substitutes such as: ABBM, Tricalcium Phosphate (TCP) with or without the addition of hyaluronic acid (HA) that were used for lateral MSA. This study population will be followed until the 3rd year. This study describes histological differences between the three groups at 9 months. All the patients enrolled in the study received a session of oral hygiene and a periodontal examination before the surgical procedure to obtain a more favorable oral environment for wound healing. A CBCT was mandatory for all included cases to verify that the maxillary sinus was clear and that the residual bone height was 3 mm or less. All the enrolled patients received 2 gr. of amoxicillin and clavulanic acid (or 600 mg. of clindamycin for those who were allergic to penicillins) as a pre-medication one-hour before surgery. All patients rinsed for 1 minute with 0.2% chlorhexidine mouthwash (and twice a day for the following 3 weeks). Local anesthesia was administered, a mid-crestal incision with mesial and distal release were performed to access the lateral bone wall of the maxillary sinus, subsequently, ultrasound bone surgery (Piezosurgery ®, Carasco, Italy) with specific tips was used for the bone window osteotomy (Figure 1-A). The Schneiderian membrane was reflected and lifted up medially with flat sinus curettes. Once the sinus membrane was completely lifted a bioabsorbable pericardium membrane (Smartbrane, Regedent AG, Zurich, Switzerland) was applied to protect it (Figure 1-B). The randomization sealed envelopes were opened and the clinician allocated the patients to one of the three experimental groups: Control group that received Demineralized Bovine Bone Mineral (Bio-Oss Cancellous, Geistlich, Wolhunsen, Switzerland); Test group 1 that received TCP with particle size ranging from 250 to 1000 µm (Osopia, Regedent, Zurich, Switzerland); Test group 2 that received TCP as in test group1 plus crosslinked Hyaluronic Acid (Hyadent BG, Regedent, Zurich, Switzerland) with a ratio 2 to 1. the bony window was repositioned, stabilized and covered with a resorbable pericardium membrane. Nine months after the MSA a CBCT analysis was required to evaluate the total bone height gain. Depending on the treatment plan, between one and three implants, bone level (BL) or tissue level (TL), of two different manufacturers (Institut Straumann AG, Basel, Switzerland and Sweden & Martina, Due Carrare, Italy) were positioned. While preparing the osteotomy implant site a bone biopsy was harvested using a trephine. The implant insertion torque was measured in Ncm for each implant. All patients were prescribed 1gr amoxicillin + clavulanic acid twice daily for 7 days (for those who were allergic to penicillin 300mg clindamycin 3 times daily for 7 days) as post-operative prophylaxis. All patients received 8mg of dexamethasone immediately after surgery and 4 mg of dexamethasone per day were prescribed for the following 5 days. Analgesics were prescribed (1gr paracetamol 3 times daily) according to patients' need. The use of removable temporary restorations was not recommended during the healing period. After an osseointegration period of 3 months, the implants were restored. The prosthetic procedures were similar for all groups, impressions were taken with a polyether rubber material (Impregum, Espe Dental AG, Seefeld, Germany) and a customized impression tray. Final Zirconia screw-retained restorations were delivered after a period of 2/3 weeks, peri-apical radiographs were taken and oral hygiene instructions were given to all participants in the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alveolar Bone Atrophy
Keywords
Bone regeneration, Biomaterial(s), Implantology, Osseointegration

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Three groups of patients will be treated with 3 different graft materials
Masking
ParticipantOutcomes Assessor
Masking Description
The envelope with the group assignment will be opened by the surgeon at the time of surgery and the patient won't be informed. The clinician who registers clinical parameters won't be informed of the group allocation. The histologist will receive biopsies with a numeric code but without informations of the graft material used.
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
Active Comparator
Arm Description
patients in the control group received Demineralized Bovine Bone Mineral for the maxillary sinus augmentation
Arm Title
Test group 1
Arm Type
Experimental
Arm Description
patients in the test group 1 received TCP with particle size from 250 to 1000 µm
Arm Title
Test group 2
Arm Type
Experimental
Arm Description
patients in the test group 2 received TCP as in test group1 plus crosslinked Hyaluronic Acid
Intervention Type
Procedure
Intervention Name(s)
Maxillary Sinus Augmentation
Intervention Description
Biomaterial Graft into the Maxillary Sinus
Intervention Type
Device
Intervention Name(s)
Maxillary Sinus Graft with ABBM
Other Intervention Name(s)
Anorganic Bovine Bone Mineral (ABBM)
Intervention Description
The maxillary sinuses in the control group are grafted with ABBM
Intervention Type
Device
Intervention Name(s)
Maxillary Sinus Graft with TCP
Other Intervention Name(s)
Tricalcium Phosphate (TCP)
Intervention Description
The maxillary sinuses in the test1 group are grafted with TCP
Intervention Type
Device
Intervention Name(s)
Maxillary Sinus Graft with TCP + HA
Other Intervention Name(s)
hyaluronic acid (HA)
Intervention Description
The maxillary sinuses in the test1 group are grafted with TCP + HA
Primary Outcome Measure Information:
Title
Histomorphometric parameters of the augmented bone (descriptive)
Description
Descriptive analysis of the specimen section at the microscope
Time Frame
9 months
Title
Histomorphometric parameters of the augmented bone (% of new bone, marrow, graft)
Description
Percentages of newly formed bone, marrow spaces and residual graft particles are reported.
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Mean bone gain measured at 9 months through CBCT evaluation
Description
radiographic evaluation
Time Frame
9 months
Title
Intra-operative
Description
clinical evaluation (yes/no) of the presence or occurrence of: sinus membrane perforation, excessive bleeding, lateral sinus cortical bone fracture.
Time Frame
During surgery
Title
Post-operative complications
Description
clinical evaluation (yes/no) of the presence or occurrence of:symptoms of acute sinusitis, swelling, suppuration, bleeding, trismus, hematoma, wound dehiscence, acute infections.
Time Frame
one week
Title
Post-operative complications
Description
clinical evaluation (yes/no) of the presence or occurrence of:symptoms of chronic sinusitis, swelling, suppuration, wound dehiscence, acute infections.
Time Frame
9 months
Title
Implant insertion torque measured in Ncm
Description
clinical evaluation
Time Frame
9 months
Title
Early implant failure
Description
clinical evaluation of the osseointegration of the implant into the bone (yes/no)
Time Frame
12 months
Title
Patient reported outcome measures
Description
All patients will answer a questionnaire regarding the oral health-related quality of life using the 14 questions of the short-form Oral Health Impact Profile (OHIP-14) (This questionnaire consists of 14 questions each one formulated in the following way: "How often (impact item) because of problems with your teeth, mouth or dentures?" The impact items belong to 7 different impact domains: 1. Functional limitations; 2. Physical pain; 3. Psychological discomfort; 4. Physical disability; 5. Psychological disability; 6. Social disability; 7. Handicap. Each question can be answered with a score from 0 to 4 corresponding to: 0 = never, 1 = hardly ever, 2 = occasionally, 3 = fairly often, and 4 = very often.)
Time Frame
9 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: need for maxillary sinus augmentation 18 years or older residual ridge height less than 3mm Exclusion Criteria: full contraindication to implant surgery, systemic diseases that could negatively influence wound healing; heavy smokers (more than 10 cigarettes/day); head and neck irradiation treatment; uncontrolled diabetes; chronic or acute sinus pathology; uncontrolled periodontal disease; full mouth plaque and bleeding score higher than 25%, tooth extractions in the previous 2 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicola A Valente, DDS, MS
Organizational Affiliation
University of Seville, Spain
Official's Role
Study Chair
Facility Information:
Facility Name
University of Geneva
City
Geneva
ZIP/Postal Code
1205
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

RCT With 3 Different Biomaterials for Maxillary Sinus Lift

We'll reach out to this number within 24 hrs